Atom | NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

Funder: National Institutes of Health (NIH)

Due Dates: November 17, 2025

Funding Amounts: No specified ceiling or floor; award size and duration depend on project needs and third-party funding; matching funds from third-party investors are required.

Summary: Supports later-stage (Phase IIB) SBIR projects to accelerate commercialization of heart, lung, blood, and sleep disorder technologies, bridging the gap between Phase II funding and regulatory approval.

Key Information: Applicants must secure third-party investment funds equal to or greater than the NHLBI request.

NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

Sign in to see full grant listing